David Blech

David Abraham Blech (born November 25, 1955) is an American businessman, investor, and venture capitalist.

David Abraham Blech (born November 25, 1955) is an American businessman, investor, and venture capitalist.

Early life and education

Blech grew up in Brooklyn, New York.[1] Blech graduated from Baruch College and earned a Master's in Music Education at the Teacher's College of Columbia University.[2]

Early career

Since 1980, Blech has founded companies and vested venture capital in the biotechnology sector. His initial venture investment, Genetic Systems Corporation, which he helped found with his father and his brother Isaac Blech, was built around promising scientists, including the high-profile microbiologist Robert Nowinski. It developed a test to diagnose sexually transmitted diseases using monoclonal antibodies.[3] The company was sold to Bristol Myers in 1986 for $294 million (3%) of Bristol Myers stock.[4]

In 1989, Blech co-founded Icos Corporation with Nowinski and George B. Rathmann, receiving the largest start up financing in biotech history at $33 million. Icos discovered the drug Cialis, which was acquired by Eli Lilly in 2003 for over $2.6 billion. The Blechs also co-founded Celgene Corporation in 1986, which was a unit of the Celanese Corporation, and was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation. As of 2012, Celgene had introduced two major cancer drugs.[5]

Other companies he helped found include DNA Plant Technology, Neurogen Corporation, Incyte Pharmaceuticals, Alexion Pharmaceuticals, ARIAD Pharmaceuticals, Neurocrine Biosciences, Cytosorbents Inc, and Intellect Neurosciences. He was also instrumental in the turnaround of Liposome Technology Inc. and Biotech General Corporation. In 1990, Blech founded D. Blech & Company, which, until it ceased doing business in September 1994, was a registered broker-dealer involved in underwriting biotechnology issues.[citation needed] At his peak in 1992, Blech's wealth was estimated at almost $300 million, briefly making him a member of the Forbes 400.[6]

Falling deep into debt, D. Blech & Co was in violation of net capital rules and ceased operations on September 22, 1994, a day that came to be known as "Blech Thursday" in the biotech industry.[5]

Blech came under investigation by the SEC for securities fraud. During the investigation Lloyd Schwed, a Florida-based attorney representing a group of former brokers, attempted to blackmail Blech by promising to withhold tapes subpoenaed during the investigation. Blech became an informant in exchange for leniency. He pleaded guilty to two counts of criminal fraud and was sentenced to a five-year term of probation.[5] A documentary film titled The Blech Effect was released in 2020 documenting his rise and fall in the industry.[7]

Personal

Blech says he is bipolar, has a gambling addiction and is a member of Gamblers Anonymous.[8][9]

References

  1. ^ Williams, Duff. "He helped create the biotech boom and when it went bust, so did he". The Seattle Times.
  2. ^ Bylinsky, Gene (June 19, 1989). "What a Way to Start a Company! A pharmaceuticals giant has put more than $70 million into Nova, a fledgling outfit that didn't even have a lab before it went public – and still hasn't marketed a product". CNN. Archived from the original on February 9, 2019.
  3. ^ "Genetic Systems, Inc". 2013. Archived from the original on September 27, 2013.
  4. ^ Walters, Donna (February 4, 1986). "Bristol-Myers Agrees to Buy Genetic Systems : Syntex Bought Out of Deal With Biotech Firm". Los Angeles Times. Retrieved February 18, 2012.
  5. ^ a b c Duff Wilson; David Heath. "He helped create the biotech boom and when it went bust so did he". Uninformed Consent. Archived from the original on February 6, 2012. Retrieved February 18, 2012.
  6. ^ William P. Barrett; Janet Novack; Daniel Fisher; Matthew Rand. "And Starting to Bark". Forbes. Retrieved February 18, 2012.
  7. ^ Whittaker, Richard (August 25, 2020). "The Blech Effect Film Review". Austin Chronicle.
  8. ^ Pollack, Andrew (September 5, 2013). "A Biotech King, Dethroned". The New York Times.
  9. ^ "David Blech Gets Four Years for Manipulating Stock Prices". Bloomberg.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.